The references used by st judes about the product date back to 1991 to 1997. Apparently dr neethling commenced his research into adapt 16 years ago (? 1998?). These products are for sale at a date pre us catdiocel approval. However Dr Neethling and the parent company of Glycan ( company associated with encap technology) both seem to be south african. Potentially similar stable but different horse.
The references used by st judes about the product date back to...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.91 |
Change
-0.090(0.50%) |
Mkt cap ! $344.2M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.75 | $74.32K | 4.151K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 681 | $17.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.25 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |